The Usefulness of Preoperative 18FDG Positron-Emission Tomography and Computed Tomography for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors
暂无分享,去创建一个
[1] M. Shimada,et al. The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors , 2013, Surgery Today.
[2] Hyundong Chae,et al. Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively , 2011, Journal of gastric cancer.
[3] M. Harada,et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. , 2010, The journal of medical investigation : JMI.
[4] S. Hirota,et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version , 2008, International Journal of Clinical Oncology.
[5] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Antonescu,et al. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.
[8] Y. Hirooka,et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy , 2007, Scandinavian journal of gastroenterology.
[9] H. Kuwano,et al. 18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors , 2005, World Journal of Surgery.
[10] J. Blay,et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Brewster,et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach , 2003, Histopathology.
[12] Y. Nakanishi,et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients , 2003, Gastric Cancer.
[13] C. Fletcher. Clinicopathologic correlations in gastrointestinal stromal tumors. , 2002, Human pathology.
[14] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[15] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[16] G. Demetri,et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.
[17] 金子 文成,et al. 長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .
[18] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[19] S. Hirota,et al. Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. , 1998, Annales chirurgiae et gynaecologiae.